Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy

Figure 3 HBsAg kinetics during entecavir treatment. A: HBsAg levels at different time points, categorized by baseline HBeAg and cirrhosis status; B: Annual HBsAg changes in different periods, categorized by baseline HBeAg and cirrhosis status; C: HBsAg levels and annual HBsAg changes, categorized by baseline HBsAg < 3 log IU/mL and ≥ 3 log IU/mL; D: HBsAg levels and annual HBsAg changes, categorized by time to virological response < 6 mo and ≥ 6 mo; E: HBsAg levels and annual HBsAg changes, categorized by HBeAg seroconversion in HBeAg-positive non-cirrhotic patients. Error bars represent 95% confidence intervals. Comparisons between different time points or periods for one patient group: ^aP < 0.05, ^bP < 0.005, ^cP < 0.001; Comparisons between different groups at one specific time point or period: ^dP < 0.05, ^eP < 0.005, ^fP < 0.001.